Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 10/20 | 0.78 |
| ▸ | AVPR1B | P47901 | 10/20 | 0.78 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.78 |
| ▸ | OXTR | P30559 | 8/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387355 | 0.92 | AVPR1A (0.73) | AVPR1AAVPR1BAVPR2OXTR | |
| Vasotocin SCHEMBL15511393 | 0.90 | OXTR (0.86) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Argiprestocin SCHEMBL30424966 | 0.90 | OXTR (0.86) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasotocin SCHEMBL13331 | 0.90 | OXTR (0.86) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasotocin SCHEMBL15511347 | 0.90 | OXTR (0.86) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Selepressin SCHEMBL19712231 | 0.89 | OXTR (0.82) | AVPR1AAVPR1BAVPR2OXTR | |
| SCHEMBL15511015 | 0.89 | OXTR (0.86) | AVPR1AAVPR1BAVPR2OXTR | |
| Selepressin SCHEMBL28487360 | 0.89 | OXTR (0.82) | AVPR1AAVPR1BAVPR2OXTR | |
| Selepressin SCHEMBL19712230 | 0.89 | OXTR (0.82) | AVPR1AAVPR1BAVPR2OXTR | |
| Vasopressin SCHEMBL1172390 | 0.89 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427612-B2 | Epimerization-free N to C solid-phase peptide synthesis | WAYNE STATE UNIVERSITY (US) | 2022-08-30 | — | — | US | disclosed |
| US-20140066373-A1 | TREATING DIABETES WITH OXYTOCIN OR OXYTOCIN ANALOGS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427612-B2 | Epimerization-free N to C solid-phase peptide synthesis | DNPEP, ANPEP, NGLY1 | AVPR1A 2353/4885AVPR1B 2793/4885AVPR2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.